During the past decade, MC "Synexus - Sofia", EOOD conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 19 clinical trials were completed, i.e. on average, 63.3% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 19 clinical trials were completed. i.e. 172.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "MC "Synexus - Sofia", EOOD" #1 sponsor was "Janssen Research & Development, LLC" with 5 trials, followed by "Genentech, Inc." with 4 trials sponsored, "Pfizer" with 3 trials sponsored, "R-Pharm International, LLC" with 3 trials sponsored and "Fresenius Kabi SwissBioSim GmbH" with 3 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "MC "Synexus - Sofia", EOOD" #1 collaborator was "OCT Clinical Trials" with 3 trials as a collaborator, "Quintiles, Inc." with 2 trials as a collaborator, "AcitGraph" with 1 trials as a collaborator, "Almac Clinical Technologies, LLC" with 1 trials as a collaborator and "Australasian Lung Cancer Trials Group" with 1 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "MC "Synexus - Sofia", EOOD" are "Rheumatoid Arthritis" (7 trials), "Arthritis, Psoriatic" (3 trials), "Dermatitis, Atopic" (2 trials), "Lupus Erythematosus, Systemic" (2 trials) and "Psoriatic Arthritis" (2 trials). Many other conditions were trialed in "MC "Synexus - Sofia", EOOD" in a lesser frequency.

Most popular intervention types in "MC "Synexus - Sofia", EOOD" are "Drug" (29 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "GDC-0853" (4 trials), "Guselkumab" (3 trials), "Adalimumab" (2 trials) and "Filgotinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "MC "Synexus - Sofia", EOOD" are 29 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "MC "Synexus - Sofia", EOOD". undefined are not yet recruiting, 5 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in MC "Synexus - Sofia", EOOD, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in MC "Synexus - Sofia", EOOD, 0 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".